1-4 of 4
statim
Close
Sort by
Journal Articles

Patients with triple-negative, JAK2 V617F- and CALR -mutated essential thrombocythemia share a unique gene expression signature

Samah Alimam, William Villiers, Richard Dillon, Michael Simpson, Manohursingh Runglall, Alexander Smith, Prodromos Chatzikyriakou, Paul Lavender, Anju Kanda, Ken Mills, Beatriz Bellosillo Paricio, James Kaufman-Cook, Sophie Ord, Shahram Kordasti, Deepti Radia, Claire Woodley, Yvonne Francis, Ghulam Mufti, Donal P. McLornan, Claire N. Harrison
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1059–1068.
https://doi.org/10.1182/bloodadvances.2020003172
Published: 2021
Includes: Supplemental data
Journal Articles

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Chaja F. Jacobs, Eric Eldering, Arnon P. Kater
Journal: Blood Advances
Blood Adv (2021) 5 (3): 913–925.
https://doi.org/10.1182/bloodadvances.2020003768
Published: 2021
Includes: Supplemental data
Journal Articles

Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro

Jan Habbel, Lucas Arnold, Yiyang Chen, Michael Möllmann, Kirsten Bruderek, Sven Brandau, Ulrich Dührsen, Maher Hanoun
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3000–3010.
https://doi.org/10.1182/bloodadvances.2019001292
Published: 2020
Includes: Supplemental data
Journal Articles

Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL

Kathryn G. Roberts, Yung-Li Yang, Debbie Payne-Turner, Wenwei Lin, Jacob K. Files, Kirsten Dickerson, Zhaohui Gu, Jack Taunton, Laura J. Janke, Taosheng Chen, Mignon L. Loh, Stephen P. Hunger, Charles G. Mullighan
Journal: Blood Advances
Blood Adv (2017) 1 (20): 1657–1671.
https://doi.org/10.1182/bloodadvances.2017011296
Published: 2017
Includes: Supplemental data